Burdaeva相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial

依贝马来诺格司亭α（一种Fc融合蛋白，长效粒细胞集落刺激因子）可降低化疗后发热性中性粒细胞减少症的风险：一项III期试验的结果

期刊:Supportive Care in Cancer

doi:10.1007/s00520-023-08176-6

Glaspy, John; Bondarenko, Igor; Burdaeva, Olga; Chen, Jianmin; Rutty, Dean; Li, Renshu; Wang, Shufang; Hou, Qingsong; Li, Simon

细胞生物学

中性粒细胞

发表日期：2023

文献求助收藏

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

阿贝西利联合氟维司群对激素受体阳性、ERBB2阴性且内分泌治疗后进展的乳腺癌患者总生存期的影响——MONARCH 2：一项随机临床试验

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2019.4782

Sledge, George W Jr; Toi, Masakazu; Neven, Patrick; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A; Koh, Han; Grischke, Eva-Maria; Conte, PierFranco; Lu, Yi; Barriga, Susana; Hurt, Karla; Frenzel, Martin; Johnston, Stephen; Llombart-Cussac, Antonio

免疫/内分泌

发表日期：2020

文献求助收藏

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

一项随机双盲临床试验，比较生物类似药 BCD-022 与参考曲妥珠单抗的安全性和有效性

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-020-07247-9

Alexeev, Sergey M; Khorinko, Andrey V; Mukhametshina, Guzel Z; Shelepen, Konstantin G; Burdaeva, Olga N; Kulik, Sergey A; Satheesh, Chiradoni Thugappa; Srivastava, Kirti; Vikranth, Mummaneni; Kryukov, Fedor; Paltusova, Anastasia N; Shustova, Mariya S; Ivanov, Roman A

发表日期：2020

文献求助收藏

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE

一项针对绝经后HER2阳性、激素受体阳性转移性乳腺癌女性患者的III期随机研究：拉帕替尼联合曲妥珠单抗和芳香化酶抑制剂双重阻断人表皮生长因子受体2 (HER2) 的疗效：ALTERNATIVE

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.2017.74.7824

Johnston, Stephen R D; Hegg, Roberto; Im, Seock-Ah; Park, In Hae; Burdaeva, Olga; Kurteva, Galina; Press, Michael F; Tjulandin, Sergei; Iwata, Hiroji; Simon, Sergio D; Kenny, Sarah; Sarp, Severine; Izquierdo, Miguel A; Williams, Lisa S; Gradishar, William J

免疫/内分泌

发表日期：2018

文献求助收藏